premature%20ejaculation
PREMATURE EJACULATION
Premature ejaculation is a male sexual dysfunction characterized by short, easily stimulated ejaculation that occurs always or nearly always before or within one minute of vaginal penetration.
It is involuntarily controlled and causes negative personal consequences like distress, frustration and avoidance of sexual intimacy.
Exact etiology and risk factors are unknown.

Introduction

  • A male sexual dysfunction characterized by:
    • Short, easily stimulated ejaculation that occurs always or nearly always before or w/in 1 minute of vaginal penetration or a clinically significant & bothersome reduction in latency time, often to about 3 minutes or less
    • Either present from the first sexual experience or following a new bothersome change in ejaculatory latency
    • Involuntarily controlled
    • Causes negative personal consequences eg distress, bother, frustration, avoidance of sexual intimacy & interpersonal difficulty
  • Most common male sexual dysfunction w/ prevalence not affected by age
    • More common in younger men

Etiology

  • Unknown exact etiology w/ few data to support the following suggested biological & psychological hypotheses including:
    • Anxiety
    • Penile hypersensitivity
    • 5-HT receptor dysfunction

Risk Factors

  • Risk factors include:
    • Genetic influences (lifelong PE)
    • Prostatic inflammation & chronic bacterial prostatitis (acquired PE)
    • Hormonal aberrations or thyroid hormone disorders
    • Poor overall health status & obesity
    • Psychological factors that may precipitate PE are historical factors (eg sexual abuse, attitude towards sex in the home), individual psychological factors (eg body image, depression, performance anxiety) or relationship factors (eg intimacy, anger)
Editor's Recommendations
Most Read Articles
15 Oct 2017
Physiotherapy and behaviour therapy appear to be effective interventions in females with overactive bladder syndrome, with those who have had no previous exposure to the treatments benefitting from post-therapy effects, a recent study has shown.
22 May 2015
A highly selective M3 antagonist developed for treating overactive bladder (OAB).